Loading...
•
Sep 30, 2022
United Therapeutics Q3 2022 Earnings Report
Reported highest quarterly revenue in history, driven by Tyvaso growth and Tyvaso DPI launch.
Key Takeaways
United Therapeutics Corporation reported a 16% year-over-year increase in total revenues for the third quarter of 2022, reaching $516.0 million compared to $444.7 million in the third quarter of 2021. Net income also increased by 47% to $239.3 million, compared to $162.7 million in the same period of the previous year.
Total revenues grew 16% year-over-year to $516.0 million.
Net income increased 47% year-over-year to $239.3 million.
Tyvaso became the first $1 billion annual run rate product.
Tyvaso DPI launch contributed to the company's growth trajectory.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
The company is focused on revenue growth, achieving 6,000 patients on Tyvaso by the end of 2022, and continuing clinical trials and research and development plans.
Positive Outlook
- Revenue growth prospects
- Goal of achieving 6,000 patients on Tyvaso by the end of 2022
- Clinical trials and other research and development plans, including the TETON studies of Tyvaso
- ADVANCE studies of ralinepag
- Clinical study of the CLES technology for EVLP
Challenges Ahead
- Risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission
- Factors that could cause actual results to differ materially from anticipated results
- Cautionary statements and risk factors set forth in periodic reports and documents filed with the Securities and Exchange Commission
- Most recent Annual Report on Form 10-K
- Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K
Revenue & Expenses
Visualization of income flow from segment revenue to net income